{"id":1012577,"date":"2026-10-22T09:35:11","date_gmt":"2026-10-22T13:35:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/"},"modified":"2026-10-22T09:35:11","modified_gmt":"2026-10-22T13:35:11","slug":"annovis-to-attend-the-ctad-2026-with-three-presentations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/","title":{"rendered":"Annovis to Attend the CTAD 2026 with Three Presentations"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Oct.  22, 2026  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will attend and present at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4zyvhc1VNVkFY0SbO_r4l0TWTLhGsbEc0pGHxzEuFIoVUmg1rEDZoYyQZMEw8DGmGAXsFvddEEumaXs6qnCJ4hJ5glnf7lP_9ksch7bEedVNOU6FpBMn-hnmfFeaZ2uEshhoNh1eWWrDygN4cxb_sQ==\" rel=\"nofollow\" target=\"_blank\">19th Clinical Trials on Alzheimer\u2019s Disease<\/a> (CTAD) conference, happening November 16-19 in Boston, MA.<\/p>\n<p>\n        <strong>Presentation details:<\/strong>\n      <\/p>\n<ol style=\"list-style-type:decimal\">\n<li>Title: \u201cRestoring proteostasis in Alzheimer&#8217;s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins\u201d<br \/>\u00a0\n<ul type=\"disc\">\n<li>Presenter: Alexander Morin, PhD, Director, Strategic Communications<\/li>\n<li>Type: Oral communications<\/li>\n<li>Section: Biotech Showcase 7<\/li>\n<li>Date &amp; time: November 19, 3:52 p.m. ET\n<p><\/li>\n<\/ul>\n<\/li>\n<li>Title: \u201cClinical trial design and baseline characteristics of buntanetap\u2019s pivotal study in treating early Alzheimer\u2019s patients\u201d\n<ul type=\"disc\">\n<li>Presenter: Cheng Fang, PhD, Chief Scientific Officer<\/li>\n<li>Type: Poster presentation (P025)<\/li>\n<li>Section: Clinical Trials \u2013 Phase IIB &amp; III<\/li>\n<li>Poster display: November 16, 2:00 p.m. \u2013 November 17, 5:30 p.m. ET\n<p><\/li>\n<\/ul>\n<\/li>\n<li>Title: \u201cPredicting blood\u2013brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer&#8217;s disease using artificial intelligence\u201d\n<ul type=\"disc\">\n<li>Presenter: Alexander Morin, PhD, Director, Strategic Communications<\/li>\n<li>Type: Poster presentation (P121)<\/li>\n<li>Section: AI-Driven Innovation in Alzheimer\u2019s Therapeutics<\/li>\n<li>Poster display: November 16, 2:00 p.m. \u2013 November 17, 5:30 p.m. ET\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<p>\u201cThree presentations at CTAD are a testament to our team\u2019s work advancing buntanetap and pushing the Alzheimer\u2019s field forward,\u201d said Maria Maccecchini, PhD, Founder, President and CEO of Annovis. \u201cOur presentations will cover buntanetap\u2019s innovative mechanism of action, our use of AI for evaluating the Alzheimer\u2019s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer\u2019s research community.\u201d<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD). The Company&#8217;s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4kW3_jvxxAvVO0TZJiy0iOrfYXI7-onnVab2pjYISGf9zllR5ICJL7nAPZi0z-pw2tqbQ_9sJN_bsh9jCnUacpLTBbzy3mnYPlH5DirCE3J5xGMkXKI0uKgDxwiGA5SZ-jzhwFYmJumiwBrAxTrosd2ON7lxVLiv9P-ykE5m0yoNef81nC8o91OVERPpOE2_WYk7r8c0OgZXV2p4xx-CSwAf0Jh48KqHl3RMu-_U1q-Qe0LIhIcq3xw71e-s50YNIbwqnpC44QiYWpeCEk0jtg==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YpdIHU_hypTxJ9xGKRE690kEDl291Z5kS8AhaV9nmlLAmo6PWfmPfvDGcmQqHvLytkaPSJA-VA480sglAx18J038ybUSf9TBHanu45GXVYcWtQrZ6dbK0wfokiTrAALHJG_b0ZfrKBYahhJ8x6kst3KNoWXokiQrSNSzr6owW6leh7HutBrUwzakn_SQSp5_Q672LdSI7KCInwKjiWgIGAwTati-iq5gXvehJFeY4yx7Y_sB44URgg4ebBffuEUa88_NC7zVF5KGuIoq7qHkztQ9Y8U8LiAjl2Z8HWlG0lq3Vsa2gSGXXV0lxDuulHK4\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0WKpPkrZzAVCr7j57gfRbf9Cphk1M3M8X7lkI5kE2C39pluqSmCrHXcpiUVGgDhAdkaBSp35FiZBLJNxMFn3zhcDBkLXEJSK4-_4jSaaCmcUqakOsKkigtehpdqKcS3oKpJU1jQQVU5oiA-wG6rGY0AobMuFwb5RzEXYHtmzW8LJuaWqkDZu9rEjmQZP5oTdgXjgXsdjsy6kJngD0ds2ot0kmgaS3mUrUpHI3yVfuz24Z3ROzHHl8czcL_QX7dwJ\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e8sav_OSIfDYeFtqvD_VWjUQB4v8R-up5KIKf_rD3O5Gwkn-SC0sN3brs-N7dIbS9FQeIG9RMz3-AAMhHOzh2o60vt_5P54xcq3rUd2PObM7gO8x_NA3bGszWwoU7gSM2hZ6iSlYmdaXCz6wRXVhne8qP236yc7YCGmSPeq4tMYDEL4guMs9byTMhJY31d0jqTBticlrKs0xItxEdmYqTw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1DQ9kLKDapmS1aA1h5o-zM79IALbl3pILQ69-oTPKs8cnJGXw3wDRz49t3KEFBr2LFbGsdzQy-VDMK9wbJGjFfn6zQY4-lR-hBc0nN6sufreDPdxUn0jP3Cs4vgImTMicaz13Bg8w5BR2XSf-Bs66vBuiRp7wOlMwUwJlGqT4h01xMWNVuFUCCS_E7HYpCzX9bPe-bqSpyf3BztrmsSieavWC5TeUDTZwqX37h_wKaKWkvdEdbClrmgRmn4E9onx8BKVX_1nv1t-NLTK-k6BcrsL2Z_P6FLcbbpPa1rHZAUN6wLPAsLTeC_aIf6Ylak_z2TdIBxGbdqzhBhxvyxBcysqcA5fxsfoNWkd5F-7jj8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4kW3_jvxxAvVO0TZJiy0iFWECmt33qEbIjmsz9aEZ5enMS2jbik6MjiGDLP-J7DtQYjHTrOhEOubNIVgz8s_7HMW8Ji7gDj2b8Qcrngue54MAFMWNrGUt_uaf66-IdpeMnG2y2ibx3u8mCDyXAe4Ob-itBE1Tyot9vXKoUj6eo20LKVSNhBEaoIxnOehw1stUq99AtarwH14iDt8declBa4OAcowrpbq9WZYZXL0hBmu9hNYQNn1_fnUIkIWbrFVvBQD1HgLYEiBRy8irDPqWw==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q_GN3kI-KtnE4rSHFjb_92eynNpgVRqkxjaekvX8R9niQxI45HNQJ9jpp3D78mv--StJcXGhEp-H7RH51ynEhSONOVW33ZjDuw6BwucSJyY=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTJhYjRmOWQtYjA3Zi00ZGZiLTliNDctOTFkYWE0ZTQ4YjgwLTEyMDY0MDMtMjAyNi0xMC0yMi1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference, happening November 16-19 in Boston, MA. Presentation details: Title: \u201cRestoring proteostasis in Alzheimer&#8217;s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins\u201d\u00a0 Presenter: Alexander Morin, PhD, Director, Strategic Communications Type: Oral communications Section: Biotech Showcase 7 Date &amp; time: November 19, 3:52 p.m. ET Title: \u201cClinical trial design and baseline characteristics of buntanetap\u2019s pivotal study in treating early Alzheimer\u2019s patients\u201d Presenter: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis to Attend the CTAD 2026 with Three Presentations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012577","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference, happening November 16-19 in Boston, MA. Presentation details: Title: \u201cRestoring proteostasis in Alzheimer&#8217;s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins\u201d\u00a0 Presenter: Alexander Morin, PhD, Director, Strategic Communications Type: Oral communications Section: Biotech Showcase 7 Date &amp; time: November 19, 3:52 p.m. ET Title: \u201cClinical trial design and baseline characteristics of buntanetap\u2019s pivotal study in treating early Alzheimer\u2019s patients\u201d Presenter: &hellip; Continue reading &quot;Annovis to Attend the CTAD 2026 with Three Presentations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T13:35:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis to Attend the CTAD 2026 with Three Presentations\",\"datePublished\":\"2026-10-22T13:35:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/\"},\"wordCount\":531,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/\",\"name\":\"Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\",\"datePublished\":\"2026-10-22T13:35:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-the-ctad-2026-with-three-presentations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis to Attend the CTAD 2026 with Three Presentations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/","og_locale":"en_US","og_type":"article","og_title":"Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk","og_description":"MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference, happening November 16-19 in Boston, MA. Presentation details: Title: \u201cRestoring proteostasis in Alzheimer&#8217;s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins\u201d\u00a0 Presenter: Alexander Morin, PhD, Director, Strategic Communications Type: Oral communications Section: Biotech Showcase 7 Date &amp; time: November 19, 3:52 p.m. ET Title: \u201cClinical trial design and baseline characteristics of buntanetap\u2019s pivotal study in treating early Alzheimer\u2019s patients\u201d Presenter: &hellip; Continue reading \"Annovis to Attend the CTAD 2026 with Three Presentations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T13:35:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis to Attend the CTAD 2026 with Three Presentations","datePublished":"2026-10-22T13:35:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/"},"wordCount":531,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/","name":"Annovis to Attend the CTAD 2026 with Three Presentations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=","datePublished":"2026-10-22T13:35:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDk4OCM3OTA5NjEwIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-the-ctad-2026-with-three-presentations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis to Attend the CTAD 2026 with Three Presentations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012577"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012577\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}